drugset / Trial / NCT04999176

Venous Thromboembolism Prophylaxis After Gynecological Pelvic Cancer Surgery With Rivaroxaban vs Enoxaparin

NCT04999176

RandomizedParallel-groupOpen-labelPrevention

Summary

The Valeria trial will provide high-quality evidence regarding the efficacy and safety of oral rivaroxaban in thromboprophylaxis after gynecological pelvic cancer surgery in comparison with standard parenteral enoxaparin.

Timeline

Start
2020-10-22
Primary completion
2024-07-15
Completion
2024-07-15

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Enoxaparin sodium Other / unclassified 40 mg Subcutaneous
Subject Rivaroxaban Other / unclassified 10 mg Oral